Submitted by Anonymous (not verified) on 5 December 2025 - 8:07
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0391/2023
Source: